94 related articles for article (PubMed ID: 8423533)
1. Identification of an orally active, nonpeptidyl oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Kishel MT; Lis EV; Reiss DR; Woyden CJ; Evans BE; Freidinger RM; Veber DF; Cook MJ
J Pharmacol Exp Ther; 1993 Jan; 264(1):308-14. PubMed ID: 8423533
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacological profile of a novel structural class of oxytocin antagonists.
Pettibone DJ; Clineschmidt BV; Lis EV; Reiss DR; Totaro JA; Woyden CJ; Bock MG; Freidinger RM; Tung RD; Veber DF
J Pharmacol Exp Ther; 1991 Jan; 256(1):304-8. PubMed ID: 1988661
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948.
Clineschmidt BV; Pettibone DJ; Reiss DR; Lis EV; Haluska GJ; Novy MJ; Cook MJ; Cukierski MA; Kaufman MJ; Bock MG
J Pharmacol Exp Ther; 1991 Mar; 256(3):827-32. PubMed ID: 2005582
[TBL] [Abstract][Full Text] [Related]
4. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
Serradeil-Le Gal C; Valette G; Foulon L; Germain G; Advenier C; Naline E; Bardou M; Martinolle JP; Pouzet B; Raufaste D; Garcia C; Double-Cazanave E; Pauly M; Pascal M; Barbier A; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2004 Apr; 309(1):414-24. PubMed ID: 14722330
[TBL] [Abstract][Full Text] [Related]
5. Progress in the development of oxytocin antagonists for use in preterm labor.
Pettibone DJ; Guidotti M; Harrell CM; Jasper JR; Lis EV; O'Brien JA; Reiss DR; Woyden CJ; Bock MG; Evans BE
Adv Exp Med Biol; 1995; 395():601-12. PubMed ID: 8714024
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
7. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
[TBL] [Abstract][Full Text] [Related]
8. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin agonist activity of a novel, potent oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Lis EV; Ransom RW; Totaro JA; Young GS; Bock MG; Freidinger RM; Veber DF; Williams PD
Eur J Pharmacol; 1991 Apr; 196(3):233-7. PubMed ID: 1893911
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of the potent oxytocin antagonist on uterine activity in the rat.
Ahn TG; Han SJ; Cho YS; An TH; Pak SC; Flouret G
In Vivo; 2004; 18(6):763-6. PubMed ID: 15646817
[TBL] [Abstract][Full Text] [Related]
11. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis.
Pettibone DJ; Clineschmidt BV; Anderson PS; Freidinger RM; Lundell GF; Koupal LR; Schwartz CD; Williamson JM; Goetz MA; Hensens OD
Endocrinology; 1989 Jul; 125(1):217-22. PubMed ID: 2544402
[TBL] [Abstract][Full Text] [Related]
12. Effect of an oxytocin antagonist on plasma oxytocin levels during nocturnal uterine contractions in the pregnant baboon.
An TH; Song CH; Choi BC; Pak SC; Mehendale R; Flouret G
Gynecol Endocrinol; 2002 Jun; 16(3):173-8. PubMed ID: 12192888
[TBL] [Abstract][Full Text] [Related]
13. Nanomolar-affinity, non-peptide oxytocin receptor antagonists.
Evans BE; Lundell GF; Gilbert KF; Bock MG; Rittle KE; Carroll LA; Williams PD; Pawluczyk JM; Leighton JL; Young MB
J Med Chem; 1993 Dec; 36(25):3993-4005. PubMed ID: 8258821
[TBL] [Abstract][Full Text] [Related]
14. Identification of functional oxytocin receptors in lactating rat mammary gland in vitro.
Pettibone DJ; Woyden CJ; Totaro JA
Eur J Pharmacol; 1990 Apr; 188(4-5):235-41. PubMed ID: 2163875
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
16. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
Bell IM; Erb JM; Freidinger RM; Gallicchio SN; Guare JP; Guidotti MT; Halpin RA; Hobbs DW; Homnick CF; Kuo MS; Lis EV; Mathre DJ; Michelson SR; Pawluczyk JM; Pettibone DJ; Reiss DR; Vickers S; Williams PD; Woyden CJ
J Med Chem; 1998 Jun; 41(12):2146-63. PubMed ID: 9622556
[TBL] [Abstract][Full Text] [Related]
17. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
18. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
19. Adaptation to pregnancy leads to attenuated rat uterine artery smooth muscle sensitivity to oxytocin.
Vedernikov YP; Betancourt A; Wentz MJ; Saade GR; Garfield RE
Am J Obstet Gynecol; 2006 Jan; 194(1):252-60. PubMed ID: 16389040
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
